Table 4.
Characteristic | Absence of clinical failure | Presence of clinical failure | p |
---|---|---|---|
n. (%) | 38 (100) | 22 (100) | |
Demographics, n. (%) | |||
Male | 22 (58) | 16 (77) | 0.251 |
Age, median (IQR) years | 71 (64–76) | 70 (65–77) | 0.842 |
Comorbidities, n. (%) | |||
Chronic Heart Failure | 27 (71) | 14 (64) | 0.552 |
Immunosuppression* | 23 (60) | 16 (73) | 0.167 |
Diabetes mellitus | 8 (21) | 3 (14) | 0.474 |
Chronic renal failure | 4 (11) | 1 (4.5) | 0.389 |
Long-Term Oxygen Therapy | 22 (58) | 7 (33) | 0.071 |
Physical findings on admission, median (IQR) | |||
Systolic blood pressure, mmHg | 130 (114–141) | 120 (104–130) | 0.037 |
Diastolic blood pressure, mmHg | 70 (70–80) | 70 (60–80) | 0.342 |
Heart Rate, beats/minute | 100 (82–112) | 102 (90–111) | 0.580 |
Respiratory rate, breaths/minute | 30 (26–32) | 35 (27–42) | 0.023 |
Respiratory rate > 30breaths/minute, n.(%) | 9 (26) | 12 (67) | 0.004 |
Oxygen saturation, % | 89 (77–94) | 85 (73–90) | 0.304 |
Laboratory values on admission, median (IQR) | |||
Arterial pH | 7.43 (7.40-7.46) | 7.45 (7.41-7.48) | 0.255 |
Arterial pH < 7.35, n. (%) | 4 (11) | 2 (9.1) | 0.616 |
PaCO2, mmHg | 40 (36–55) | 38 (33–43) | 0.163 |
PaO2, mmHg | 49 (40–65) | 49 (38–72) | 0.945 |
PaO2/FiO2 ratio | 131 (95–184) | 104 (84–135) | 0.078 |
White blood cells, cell/L-1 | 11820 (7975–15140) | 13860 (8515–15632) | 0.363 |
Radiological appearance of pulmonary fibrosis, n. (%) | |||
Usual Interstitial Pneumonia | 15 (40) | 13 (59) | 0.142 |
Non-Specific Interstitial Pneumonia | 8 (21) | 6 (27) | 0.583 |
*Immunosuppression defined as the presence of any among: long term corticosteroid, immunosuppressive therapy, active cancer.